🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
Organization STANFORD UNIVERSITYLocation STANFORD, UNITED STATESPosted 4 Mar 2021Deadline 28 Feb 2026 ⚠️
NIHUS FederalResearch GrantFY2025Antibody-drug conjugatesAssayB Cell-Activating Factor ReceptorB-Cell Stimulatory Factor 1 GeneBSF-1 GeneBSF1 GeneBioassayBiological AssayBiological MarkersBiotechBiotechnologyBloodBlood PlasmaBlood Reticuloendothelial SystemBurkitt HerpesvirusBurkitt Lymphoma VirusCD124 AntigensCDw124 AntigenCancer PatientCancersCell BodyCell Communication and SignalingCell SignalingCellsClinicalClinical MarkersCytotoxic ChemotherapyCytotoxic TherapyD12S1644DNA mutationDependenceDevelopmentDiagnosisDiseaseDisease remissionDisorderDoctor of MedicineDoctor of PhilosophyEB virusEBVEpstein Barr VirusEventFailureFrequenciesGene variantGeneticGenetic ChangeGenetic defectGenetic mutationGenomicsGenotypeGoalsHHV-4HHV4HeterogeneityHodgkin DiseaseHodgkin DisorderHodgkin lymphomaHodgkin'sHodgkin's LymphomaHodgkin's diseaseHodgkins lymphomaHumanHuman Herpesvirus 4IL-4 GeneIL-4 ReceptorsIL-4-STATIL4IL4 ReceptorsIL4 geneImageIndividualIndividualized risk predictionInfectious Mononucleosis VirusInterleukin 4 ReceptorInterleukin-4 GeneInterleukin-4 Precursor GeneInterleukin-4 Receptor AlphaIntracellular Communication and SignalingM.D.Malignant CellMalignant LymphogranulomaMalignant NeoplasmsMalignant TumorMeasurableMeasurementMeasuresMetabolicMethodsModelingModern ManMolecularMonitorMutationNatureOutcomePETPET ScanPET imagingPETSCANPETTPathologicPathway interactionsPatientsPh.D.PhDPhenotypePlasmaPlasma SerumPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrecision therapeuticsPredicting RiskPrediction of Response to TherapyPropertyPublic HealthRad.-PETRecurrenceRecurrentRegimenRemissionReticuloendothelial System, Serum, PlasmaRiskRisk FactorsSTAT6STAT6 geneSTAT6BSTAT6CSignal TransductionSignal Transduction SystemsSignalingSomatic MutationStereotypingTechniquesTestingTherapeuticTherapeutically TargetableToxic effectToxicitiesToxicity due to chemotherapyTreatment EfficacyTreatment FailureTreatment outcomeTumor CellTumor TissueTumor VolumeVariantVariationViral GenomeWorkallelic variantbio-markersbiologic markerbiological heterogeneitybiological signal transductionbiomarkercancer cellcancer imagingcheck point blockadecheckpoint blockadechemotherapy toxicitycirculating tumor DNA assaycirculating tumor DNA assessmentcirculating tumor DNA evaluationcirculating tumor DNA monitoringcirculating tumor DNA profilingcirculating tumor DNA screeningcirculating tumor DNA testingclinical biomarkersclinical heterogeneityclinically useful biomarkerscohortcopy number alterationctDNA assayctDNA assessmentctDNA evaluationctDNA monitoringctDNA profilingctDNA screeningctDNA testingcytokinedevelopmentaldisease riskdisorder riskexomeexperimentexperimental researchexperimental studyexperimentsforecasting riskgain of functiongenetic variantgenome mutationgenomic varianthigh riskiPSiPSCiPSCsimage-based methodimagingimaging methodimaging modalityimaging studyimmune check point blockadeimmune checkpoint blockadeimprovedindexinginduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinnovateinnovationinnovativeinsightintegration siteinterleukin-4 Statintervention efficacyliquid biopsymalignancymolecular biomarkermolecular markerneoplasm/cancerneoplastic cellnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachoncologic imagingoncology imagingoutcome predictionpathwaypersonalization of treatmentpersonalized medicinepersonalized risk predictionpersonalized therapypersonalized treatmentpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypre-clinicalprecision medicineprecision therapiesprecision treatmentprecision-based medicinepreclinicalpredict riskpredict riskspredict therapeutic responsepredict therapy responsepredicted riskpredicted riskspredicting riskspredictive riskpredicts riskprognosticationresponseresponse biomarkerresponse markersrisk predictionrisk prediction algorithmrisk prediction modelrisk predictionssomatic varianttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapeutic outcometherapeutic targettherapy efficacytherapy failuretherapy outcometherapy predictiontreatment predictiontreatment response predictiontumortumor DNAtumor cell DNAtumor imagingtumor-specific DNAvirus genome
Applications closed.
Description preview
PROJECT SUMMARY/ABSTRACT
PIs: Ash Alizadeh, M.D./Ph.D. & Maximilian Diehn, M.D./Ph.D.
Classical Hodgkin lymphoma (HL) is among the most curable human malignancies. However,
strategies to personalize HL therapies and to minimize long-term attendant toxicities of
chemotherapy are currently limited to baseline risk factors and imaging. This is due to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click